Search academic texts

Information × Registration Number 0224U033545, (0121U111834) , R & D reports Title Develop tactics and strategies for the treatment of complications of COVID 19 in cardiac surgery patients with acquired heart defects popup.stage_title Розробити тактику та стратегію лікування ускладнень COVID 19 у кардіохірургічних хворих з набутими вадами серця Head Krykunov Oleksii A., Доктор медичних наук Registration Date 30-12-2024 Organization State Institution "National Institute of Cardiovascular Surgery named after MM Amosov of the National Academy of Medical Sciences of Ukraine" popup.description1 Develop methods for the treatment of cardiac surgery patients with acquired heart defects after a complicated course of COVID 19 popup.description2 The study analyzed the features of the course and treatment of patients with acquired heart disease (CHD) infected with SARS-CoV-2 in the perioperative period. A total of 164 patients with a mean age of 61 years (range, 49 to 71 years) were included, of whom 61.6% were men and 38.4% were women. The results of the study showed that a mild and moderate course of COVID-19 was observed in 69.5% of patients, while a severe course was noted in 30.5%. Among the main complications were acute lung damage (12.8%), kidney damage (7.9%), HF (9.1%), and central nervous system (CNS) damage (1.8%). All patients received surgical treatment, including correction of aortic (40.9%), mitral (34.1%), and mitral-aortic (25.0%) heart defects. Postoperative complications included cardiac arrhythmias (arrhythmias) in 12.2% of cases and acute renal failure (ARF) in 6.1% of patients. To improve treatment results, immunosuppressive therapy (cyclophosphamide), hemoadsorption, renal replacement therapy, and protective lung ventilation were used. Algorithms for intraoperative protection of target organs, in particular the lungs and central nervous system, were developed, which contributed to a reduction in the level of complications and an improvement in the general condition of patients. Overall in-hospital mortality was 10.9%, with the highest mortality rate (21.6%) occurring in the first month after receiving a negative SARS-CoV-2 test. The introduction of innovative treatment methods made it possible to reduce the mortality rate by half - from 13.2% to 6.0%. The study demonstrates that the combination of intensive care, specialized perioperative treatment protocols and innovative approaches significantly improves the treatment outcomes of patients with complications of COVID-19 and HCV. The developed methods have the potential for further implementation in clinical practice, which can help reduce mortality and improve the quality of life of patients with complex cardiac pathologies against t  Product Description popup.authors Hrubiak Liliana M. Zakharova Valentyna P. Koltunova Hanna B. Kosovan Dmytro M. Oleksii A. Krykunov Luchynets Oleksandr F. Malysheva Tetiana A. Rudenko Olena V. Senko Oleksandr H. Sobirov Barno Bobir ogly Soltani Siuzanna E. Shnaider Liudmyla M. popup.nrat_date 2024-12-30 Close